Contemporary Evaluation of the D'Amico Risk Classification of Prostate Cancer

Urology

Volumn 70, Issue 5, 2007, Pages 931-935

  Hernandez, David J ^a   Nielsen, Matthew E ^a   Han, Misop ^a   Partin, Alan W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RECURRENCE; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 36549047063     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.08.055     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
3. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166 (2001) 2185-2188
4. Lee A.K., Schultz D., Renshaw A.A., et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 673-677
5. Lieberfarb M.E., Schultz D., Whittington R., et al. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys 53 (2002) 898-903
6. Chun F.K., Karakiewicz P.I., Briganti A., et al. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int 99 (2007) 794-800
7. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
8. Han M., Partin A.W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169 (2003) 517-523
9. Poulakis V., Witzsch U., de Vries R., et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy. Urology 64 (2004) 1165-1170
10. Graefen M., Noldus J., Pichlmeier U., et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 36 (1999) 21-30
11. Amling C.L., Blute M.L., Lerner S.E., et al. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 73 (1998) 401-406
12. Han M., Partin A.W., Piantadosi S., et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 166 (2001) 416-419
13. Ung J.O., Richie J.P., Chen M.H., et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60 (2002) 458-463
14. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
15. Tornblom M., Eriksson H., Franzen S., et al. Lead time associated with screening for prostate cancer. Int J Cancer 108 (2004) 122-129
16. Derweesh I.H., Kupelian P.A., Zippe C., et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 22 (2004) 300-306
17. Han M., Partin A.W., Chan D.Y., et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 171 (2004) 23-26
18. Bova G.S., Fox W.M., and Epstein J.I. Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol 6 (1993) 201-207
19. Hall G.S., Kramer C.E., and Epstein J.I. Evaluation of radical prostatectomy specimens: a comparative analysis of sampling methods. Am J Surg Pathol 16 (1992) 315-324
20. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Gretzer M.B., Trock B.J., Han M., et al. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 168 (2002) 1419-1422
22. Mitchell J.A., Cooperberg M.R., Elkin E.P., et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 173 (2005) 1126-1131
23. Chun F.K., Graefen M., Zacharias M., et al. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 24 (2006) 273-280
24. Cooperberg M.R., Lubeck D.P., Mehta S.S., et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170 (2003) S21-S25 discussion S26-S27